The Link Between Metformin and Cancer Prevention

Metformin, the most widely prescribed pill for type 2 diabetes, has for years been linked with lower rates of several cancers among the people who take it.1PubMed Central. Metformin in cancer prevention and therapy How big that link really is depends heavily on how the studies were built, and some of the most striking benefits shrink or vanish when the counting is done carefully.2PubMed Central. Metformin and the Risk of Cancer For most people, that makes it a reason for cautious interest, not a reason to start or switch medicines.

Which Cancers Metformin Has Been Linked To

Liver cancer shows the most consistent link. Every study in one review of people with diabetes found that metformin users had a lower risk of liver cancer than people on other diabetes drugs.3PubMed. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review Combined, those studies put the risk at roughly half.4PubMed. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review In people with diabetes who had been cured of hepatitis C, about 3 in 100 metformin users developed liver cancer within 5 years, versus about 11 in 100 non-users.5PubMed. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan That puts metformin users close to the risk of people without diabetes, about 3 in 100.6PubMed. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan

The liver may benefit most because of how the pill travels. Swallowed metformin goes from the gut to the liver before it reaches the rest of the body, and liver cells take it up easily, so the liver sees high levels.7Cancer Discovery. Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning

Still, a liver cancer link in diabetes doesn’t mean metformin protects everyone’s liver. Diabetes itself raises liver cancer risk, so the comparison group of people on other diabetes drugs matters. The hepatitis C figures come from people already cured of the virus, a specific group, and shouldn’t be stretched to everyone with fatty liver or other liver disease. And even a roughly halved risk is a relative figure, so the actual chance of liver cancer depends on how much liver disease a person already has.

Colorectal cancer and its warning growths also show a link. Across 37 studies of more than 1.4 million people with no prior bowel growths, metformin users had about a 20% lower risk of colorectal growths and cancer.8PubMed Central. Metformin for primary prevention of colorectal neoplasms in adenoma-free populations: a systematic review and dose-response meta-analysis

A polyp is a small growth on the bowel lining. Most stay harmless, but some types can slowly turn into cancer over years. Researchers count polyps because they show up sooner than cancers, so a trial can see an effect without waiting decades. A drop in polyps is a hint about cancer prevention, not proof, because not every polyp would have become cancer. Screening such as colonoscopy finds and removes polyps directly, which metformin does not replace.

One trial, where chance decided who took metformin, found that about 31% of metformin takers developed polyps, versus about 52% on a dummy pill.9PubMed Central. Metformin and Colorectal Cancer Because chance assigned the drug, the difference is less likely to come from the groups being different at the start. But polyp trials are usually fairly small and short compared with the 37-study pooled results, so the size of the effect could change with larger trials. Fewer polyps also isn’t the same as fewer deaths from colorectal cancer, which would take larger, longer trials to show.

Prostate and stomach cancer results are weak or empty. One pooled analysis found metformin users got prostate cancer about 12% less often, but it found no fewer deaths or prostate cancer returns among users.10PubMed. Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis In a large prostate study, metformin use made no difference to the chance of a prostate cancer diagnosis.11PubMed Central. Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study For stomach cancer, careful studies found no protective effect at all.12PubMed. Immortal time bias exaggerates the effect of metformin on the risk of gastric cancer: A meta-analysis

Why Early Results Looked Too Good

Most of the evidence comes from observational studies, which look back at people who happened to take metformin and those who didn’t. These studies use existing records, which makes them quick and cheap and lets them cover huge numbers of people. They can show that two things go together, but they can’t show that one caused the other, because people who get metformin differ from those who don’t. Doctors choose who gets it based on kidney function, other illnesses and how well someone is doing, all of which also affect cancer risk.

On top of that, in at least 13 such studies, people were counted as metformin users for a stretch of time before they actually started it, a period in which they could not yet have been diagnosed or died in the metformin group.13PubMed Central. Metformin and the Risk of Cancer Anything that happened before starting couldn’t count against metformin, which makes users look healthier than they were.

Those errors produced cancer reductions ranging from 20% to 94%.14PubMed Central. Metformin and the Risk of Cancer A spread that wide suggests the method is producing the number. The larger the free stretch, the bigger the apparent benefit.

Three studies that avoided these mistakes found metformin had no effect on how often cancer occurred.15PubMed Central. Metformin and the Risk of Cancer Those three matter more than the many flawed ones.

Fixing the counting erases much of the benefit. For stomach cancer, flawed studies showed a 33% lower risk with metformin, while sound studies showed none.16PubMed. Immortal time bias exaggerates the effect of metformin on the risk of gastric cancer: A meta-analysis In women with diabetes and breast cancer, a simple comparison suggested metformin users were about 55% less likely to die of breast cancer, but a more careful method on the same kind of data found no difference.17PubMed. Metformin to treat breast cancer: an application of the prevalent new-user design for observational studies with no active comparator

Diabetes treatment itself muddies comparisons. Metformin is usually the first diabetes drug people get, so non-users are often people further along in their diabetes on second- or third-line drugs.18PubMed Central. Metformin and the Risk of Cancer Comparing them can make metformin look protective when the real difference is how advanced the diabetes is.

Randomized trials, where chance decides who gets the drug, settle the question better, but few such trials exist yet for cancer prevention, and until they do, headline percentages from studies that simply compare people who happened to take the drug with people who didn’t should be read with caution.

How Metformin Might Slow Cancer

Metformin blocks part of the cell’s power plants.19PubMed Central. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis These turn food into the usable energy that cells run on, so partly blocking them is like turning down a power supply, and cells have less usable energy as the dose rises.20PubMed Central. Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis In the lab, cancer cells grew more slowly, and died when they were also short of sugar.21PubMed Central. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

Low energy also flips a cell’s fuel gauge. The cell activates a sensor that tells it to conserve resources rather than grow, and that sensor shuts down a main growth switch that cancer cells rely on.22PubMed Central. Metformin targets multiple signaling pathways in cancer This has been seen in lab work, not shown in patients.

Metformin works on hormones and immunity too. In a trial of women without diabetes with advanced breast cancer, adding metformin to chemotherapy lowered an insulin-like growth hormone and reduced deaths.23PubMed. Targeting insulin-like growth factor-1 (IGF-1) by using metformin in non-diabetic metastatic breast cancer female patients: a randomized controlled trial In lab and animal work, metformin helped cancer-fighting immune cells survive the low-oxygen conditions inside tumors.24PubMed Central. Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression It may also change gut bacteria in ways that reduce bowel tumors in animals.25PubMed Central. Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis

Insulin may be part of the story. High insulin and related hormones can encourage cells to grow, and type 2 diabetes often comes with high insulin levels. Metformin lowers blood sugar partly by reducing how much sugar the liver releases, which lowers insulin. That is one reason the benefit might be bigger in people with diabetes.

Lab doses, though, are far above real-life levels. Levels reached in people’s blood and tumors are about 100 to 1,000 times lower than those used in many lab experiments.26PubMed Central. Tumor, whole blood, plasma, and tissue concentrations of metformin in lung cancer patients Effects seen in dishes may not happen at the dose in a diabetes prescription. The effect depends on dose, which is why the gap between lab and human levels matters. Many lab and animal studies showed benefits, yet breast cancer trials in people often did not show longer survival.27PubMed Central. Metformin and Breast Cancer: Current Findings and Future Perspectives from Preclinical and Clinical Studies

Metformin for People Who Already Have Cancer

Results in people with diabetes and cancer are mixed. In one study of women with diabetes and early breast cancer, 92% of metformin users were alive at 5 years versus 59% of non-users.28PubMed Central. The Effect of Metformin on Survival Outcomes of Non-Metastatic Breast Cancer Patients with Type 2 Diabetes That gap is bigger than almost any real cancer treatment produces, and this kind of comparison is prone to the counting errors described earlier. Metformin users may have been healthier or earlier in their diabetes.

In men with advanced prostate cancer on hormone therapy, starting metformin did not improve survival.29PubMed Central. Effects of Metformin on Cancer Survival Among Men Diagnosed with Advanced Prostate Cancer Treated with Androgen-Deprivation Therapy: Emulating a Target Trial Here men were started on metformin as part of treatment and compared by chance, which contrasts with the optimistic comparisons of existing users and shows how study design changes the answer. Advanced cancer is a hard setting, and a lack of benefit there does not rule out a role earlier on.

In people with cancer but no diabetes, clinical trial results have not been as good as expected.30PubMed Central. Metformin: current clinical applications in nondiabetic patients with cancer The best dose, schedule and length of treatment are still unknown, and trials used metformin differently.31PubMed Central. Metformin: current clinical applications in nondiabetic patients with cancer Some people also develop side effects they tolerate poorly.32PubMed Central. Metformin: current clinical applications in nondiabetic patients with cancer Without diabetes, metformin’s blood-sugar and insulin effects have less room to help, so the benefit seen in diabetes studies may not carry over.

Researchers are testing it as a partner drug. In a small ovarian cancer trial, metformin reduced cancer cells thought to drive relapse, and tumor cells stayed more sensitive to platinum chemotherapy.33JCI Insight. Phase II clinical trial of metformin as a cancer stem cell–targeting agent in ovarian cancer Combining metformin with immunotherapy drugs is considered promising but still under study.34PubMed Central. Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect Tumors with certain gene changes may respond better, so future use may depend on tumor testing.35PubMed. Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery

If you have cancer and diabetes, keep taking metformin for diabetes as prescribed unless your doctors change it. Tell your oncologist every diabetes medicine you take, and ask whether any metformin trial fits your cancer type.

Should You Take Metformin to Prevent Cancer

Neither the U.S. FDA nor Europe’s EMA has approved metformin for solid tumors, and the evidence remains provisional.36PubMed Central. Repurposing Metformin in Precision Oncology: Mechanistic Insights, Biomarker-Guided Strategies, and Translational Imperatives It is sometimes prescribed off-label, meaning for a use the drug isn’t approved for, mainly because it is cheap.37PubMed Central. Repurposing Metformin in Precision Oncology: Mechanistic Insights, Biomarker-Guided Strategies, and Translational Imperatives Being given alongside chemotherapy in a hospital doesn’t mean it carries the same proof as the main treatment.38PubMed Central. Repurposing Metformin in Precision Oncology: Mechanistic Insights, Biomarker-Guided Strategies, and Translational Imperatives

The strongest cancer links come from people with diabetes, often compared with people on other diabetes drugs.39PubMed. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review No study here shows that a healthy person without diabetes gets the same protection. Common side effects include stomach upset and diarrhea, and long-term use can lower vitamin B12. If you’re interested, discuss it with your doctor rather than obtaining it yourself.

Metformin has a long safety record in diabetes, but that record is in people who need it for blood sugar, where benefits outweigh side effects. In someone without diabetes, any side effects carry no offsetting diabetes benefit, and the cancer benefit is unproven.

If you already take metformin for diabetes, it is a good first-line drug regardless of cancer, and cancer is no reason to stop it. Any cancer benefit is a possible bonus, not a reason to skip screening. Keep up the colonoscopy, mammograms and liver checks your doctor recommends. If you have hepatitis or fatty liver, ask about liver cancer surveillance.

What lowers cancer risk with proven results is more ordinary: not smoking and limiting alcohol, keeping blood sugar and weight under control (which also lowers insulin), getting recommended screening tests that catch early disease, and vaccines such as hepatitis B and HPV.

Where the Research Is Heading

The next step is matching the drug to the right people. Metformin may kill cancer cells mainly when a tumor has a specific genetic defect that the person’s healthy cells lack, so it could act on cancer while sparing normal tissue.40Cancer Discovery. Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning These defects show up in some lung and endometrial cancers.41Cancer Discovery. Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning Such tumors have lost a repair or sensing function that healthy cells still have, which makes them more reliant on certain energy pathways. If metformin hits that pathway, normal cells can compensate while tumor cells can’t. This remains a hypothesis, tested in lab models and early studies, not an established treatment approach.

If you want to find or judge a trial, search clinicaltrials.gov for metformin and your cancer type. Check whether chance decides who gets the drug, and ask what outcome is measured, such as survival, not just lab markers. It’s also fair to ask who pays and how side effects are monitored.